Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News Atossa Therapeutics (NASDAQ: ATOS) deepens Z-endoxifen bet as 2025 losses widen and rare disease optionality grows Atossa Therapeutics widened its 2025 loss as Z-endoxifen spending rose and rare disease optionality expanded. Read what this could mean for ATOS. byVenkateshMarch 26, 2026